Andrew M. Hoffman, DVM, DVSc, DACVIM
Additional Titles:
Gilbert S. Kahn Dean of Veterinary Medicine
Dr. Andrew Hoffman is a large animal veterinarian who started his career in rural New England private practice. He is the Gilbert S. Kahn Dean of Veterinary Medicine at the University of Pennsylvania since 2018. Prior to his appointment as Dean, he was faculty at Tufts University for 24 years, where he assumed numerous leadership roles: Director of Equine Sports Medicine; Director of the Lung Function Testing Laboratory; Director of the Stem Cell Laboratory; and Director of the Regenerative Medicine Laboratory. His over 20 years of continuous NIH funding focused on therapies for emphysema and asthma, including AeriSealTM for human emphysema currently in U.S. clinical trials, and AeroHippusTM, which is the inhaler for treatment of equine asthma. Hoffman also developed a spectrum of non-invasive diagnostic lung function tests in animals ranging from mice to bottlenose dolphins to elephants.
At the University of Pennsylvania (Penn) he founded the first Extracellular Vesicle core in the U.S. As Dean, Hoffman has focused on interdisciplinary and interprofessional scholarship for the veterinary profession including new dual degrees for VMD students, and founding the Institute of Infectious and Zoonotic Diseases, Center for Stewardship Agriculture and Food Security, and Wildlife Futures Program. He is a member of the National Academy of Practice, and serves on several advisory groups related to climate change, including founding Chair of the Climate Change Task Force of the American Association of Veterinary Medical Colleges, the National Academy of Medicine Action Collaborative (Education committee), the National Academy of Science Engineering and Medicine Environmental Health working subgroup, the Methane and Health working group of the Environmental Defense Fund, and Advisory Council for the Environmental Innovations Initiative among other things. See Hoffman’s climate-focused activities.
Borel, F., Sun, H., Zieger, M., Cox, A., Cardozo, B., Li, W., Oliveira, G., Davis, A., Gruntman, A., Flotte, T. R., Brodsky, M. H., Hoffman, A. M., Elmallah, M. K., Mueller, C. Editing out five Serpina1 paralogs to create a mouse model of genetic emphysema Proc Natl Acad Sci U S A 115: 2788-2793, 2018.
Yang, V. K., Tai, A. K., Huh, T. P., Meola, D. M., Juhr, C. M., Robinson, N. A., Hoffman, A. M.Dysregulation of valvular interstitial cell let-7c, miR-17, miR-20a, and miR-30d in naturally occurring canine myxomatous mitral valve disease PLoS One 13: e0188617, 2018.
Davis, A. M., Thane, K. E., Hoffman, A. M. Practical methods for assessing emphysema severity based on estimation of linear mean intercept (lm) in the context of animal models of alpha-1 antitrypsin deficiency Methods Mol Biol 1639: 93-106, 2017.
Yang, V. K., Loughran, K. A., Meola, D. M., Juhr, C. M., Thane, K. E., Davis, A. M., Hoffman, A. M. Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model J Extracell Vesicles 6: 1350088, 2017.
Wichtel M, Gomez D, Burton S, Wichtel J, Hoffman AM. Relationships between equine airway reactivity measured by flowmetric plethysmography and specific indicators of airway inflammation in horses with suspected inflammatory airway disease. Equine Vet J 48: 466-71, 2016.
Platz, J., Bonenfant, N. R., Uhl, F. E., Coffey, A. L., McKnight, T., Parsons, C., Sokocevic, D., Borg, Z. D., Lam, Y. W., Deng, B., Fields, J. G., DeSarno, M., Loi, R., Hoffman, A. M., Bianchi, J., Dacken, B., Petersen, T., Wagner, D. E., Weiss, D. J. Comparative decellularization and recellularization of wild-type and alpha 1,3 galactosyltransferase knockout pig lungs: A model for ex vivo xenogeneic lung bioengineering and transplantation Tissue Eng Part C Methods 22: 725-39, 2016.
Rettmer, H., Hoffman, A. M., Lanz, S., Oertly, M., Gerber, V. Owner-reported coughing and nasal discharge are associated with clinical findings, arterial oxygen tension, mucus score and bronchoprovocation in horses with recurrent airway obstruction in a field setting Equine Vet J 47: 291-5, 2015.
Graham, J. E., Meola, D. M., Kini, N. R., Hoffman, A. M. Comparison of the effects of glycerol, dimethyl sulfoxide, and hydroxyethyl starch solutions for cryopreservation of avian red blood cells Am J Vet Res 76: 487-93, 2015.
Houtsma, A., Bedenice, D., Pusterla, N., Pugliese, B., Mapes, S., Hoffman, A. M., Paxson, J., Rozanski, E., Mukherjee, J., Wigley, M., Mazan, M. R. Association between inflammatory airway disease of horses and exposure to respiratory viruses: a case control study Multidiscip Respir Med 10: 33, 2015.
Cruz, F. F., Borg, Z. D., Goodwin, M., Sokocevic, D., Wagner, D. E., Coffey, A., Antunes, M., Robinson, K. L., Mitsialis, S. A., Kourembanas, S., Thane, K., Hoffman, A. M., McKenna, D. H., Rocco, P. R., Weiss, D. J. Systemic administration of human bone marrow-derived mesenchymal stromal cell extracellular vesicles ameliorates aspergillus hyphal extract-induced allergic airway inflammation in immunocompetent mice Stem Cells Transl Med 4: 1302-16, 2015.
Dr. Hoffman has extensive experience, publications (~100), and patents (4) concerning novel methods of evaluation or therapies in spontaneous and experimental disease models in large animals. He also has ~15 yrs experience specifically in the development of preclinical large animal models in accordance with Good Laboratory Practices (GLP), including as PI/PD in a current study funded by NIH (RO1-HL112987-01A1) “Autologous Lung Derived Mesenchymal Stromal Cell Therapy for Emphysema”. Importantly this active study includes GLP-like pre-clinical studies in a large animal (sheep) model of emphysema followed by the first-in-human Phase 1 investigation of autologous LMSCs therapy for advanced emphysema in years 4-5, the latter under the direction of Edward P. Ingenito MD, PhD (PD/PI, Brigham and Womens Hospital).
Previously Drs. Hoffman and Ingenito developed major advances in human emphysema therapy, specifically non-surgical methods for lung volume reduction which are currently in Phase III again successfully linking pre-clinical large animal models with human studies. In addition, Dr. Hoffman’s laboratory serves as a Regenerative Medicine / Stem Cell core and project leader on several studies involving canine, feline, and avian species funded by a variety of Foundations and industry partners.
These multifaceted experiences have given the PD/PI the experience to lead multi-disciplinary projects involving stem cell implantations, bioengineering technologies, large animal experimental or spontaneous models, cell-molecular biology, biomarker analyses, clinical trial design, and FDA (GLP, GCP, GMP) compliance.
University of Guelph, Ontario Veterinary College, Ontario, Canada (1987 to 1991)
Residency/DVSc (Doctor of Veterinary Science) combined program
University of Guelph, Ontario, Canada (1991 to 1992)
Fellow, EP Taylor Foundation of Ontario
Hebrew University (1992 to 1994)
Fellow, Lady Davis Foundation of Montreal
Clinical Specialties:
Pulmonary Physiology, Cellular and Molecular Biology, Regenerative Medicine
Research:
Education:
DVM (Veterinary Medicine) Cornell University College of Veterinary Medicine, 1985; DVSc (Pharmacology) University of Guelph, Ontario, 1990
Board Certification:
Diplomate, American College of Veterinary Internal Medicine-Large Animal
Contact:
University of Pennsylvania
School of Veterinary Medicine
3800 Spruce Street
Philadelphia, PA 19104